Science

Zantrene® (bisantrene dihydrochloride) is a small molecule anti-cancer drug which has clinical and preclinical efficacy as both a low dose, highly targeted precision oncology agent and cardio-protective chemotherapeutic. The recent identification that Zantrane® is an highly potent FTO inhibitor has driven intense scientific and clinical interest in Zantrene as a rapidly translatable pharmaceutical able to target the m6A RNA methylation pathway. https://youtu.be/BiM2feiwPs0 History of Zantrene Zantrene® was originally developed by Lederle Laboratories in the 1970s as a lower cardiotoxic alternative to the commonly used anthracycline chemotherapeutics. Lederle trialled Zantrene on a…

Latest News

+

21 December 2021 – Race Oncology Limited (“Race”) is pleased to announce that its Share Purchase Plan (SPP) has closed…

https://www.youtube.com/watch?v=wAsG9ZcRAyE